Their research groups have carried out the largest vaccine study with HIV infected patients in the UK to date. Over 900 recently diagnosed HIV patients on the study received vaccines against various diseases and infections. The results showed that one vaccine in particular, Menitorix, was particularly effective, with over half of the patients achieving protection against a number of bacterial infections including Meningitis C.
Sian Faustini, PhD student in Professor Drayson’s research group, said of the group’s latest findings: “These results support the concept of early vaccination following a positive HIV diagnosis. They also suggest that vaccination with Prevenar-13 (PCV-13) has a positive impact on reducing hospital admission rates and length of stay, when compared with the vaccine, Pneumovax-23, ( PPV-23), which is currently routinely used. The findings from this study will be published in the team’s second paper - watch this space!”